Loading…
Loading…
OHCS does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for OHCS and 80,000+ other tickers.
See exactly how OHCS's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for OHCS and 80,000+ other tickers.
Optimus Healthcare Services, Inc., based in Westbury, New York, operates in two key areas within the healthcare sector. Firstly, the company empowers community oncology practices by providing the essential infrastructure and support required to enroll their patients in clinical trials. Optimus also partners with pharmaceutical companies and contract research organizations (CROs) to conduct comprehensive clinical studies, spanning all phases (I-IV), for investigational drugs, biologics, and medical devices. Secondly, Optimus manages a software-as-a-service (SaaS) platform that integrates…
NEW YORK, NY / ACCESSWIRE / August 17, 2023 / Optimus Healthcare Services, Inc. (OTC PINK:OHCS) announced today the appointment three directors to its Board of Directors: Teresa Carlson, Dr. Eli Avila, and Dr. Peter Michalos IV. Teresa Carlson currently serves as President and Chief Commercial Officer of Flexport, Inc. Previously Ms.
NEW YORK, NY / ACCESSWIRE / August 16, 2023 / Optimus Healthcare Services, Inc. (OTC PINK:OHCS), announced today that it has entered into a Memorandum of Understanding with RUA Diagnostics, Inc., wherein the parties may negotiate a joint venture agreement for the purpose of commercializing a diagnostic device based on the Patent License Agreement ("Agreement") entered between RUA and the Regents of the University of Michigan. The Agreement includes dozens of U.S. and international patents regarding the use of micro-gas chromatography and miniature gas detectors used in conjunction with related software and artificial intelligence for breath analysis for the diagnosis of human and animal disease states.